Two Completely Different Philosophies
AOD-9604 and GLP-1 agonists both appear in the OSYRIS Metabolic category, but they represent fundamentally different approaches to studying fat metabolism:
AOD-9604 acts on fat tissue directly. It activates beta-3 adrenergic receptors on adipocytes, triggering hormone-sensitive lipase to release fatty acids from stored triglycerides. It also inhibits lipogenic enzymes, reducing new fat synthesis. AOD-9604 doesn't affect appetite, insulin, glucose, or IGF-1 — it's a targeted intervention on adipose tissue metabolism.
GLP-1 agonists act on the brain and pancreas. They suppress appetite through hypothalamic and brainstem signaling, enhance glucose-dependent insulin secretion, and slow gastric emptying. Fat loss occurs as a downstream consequence of reduced caloric intake — not through direct action on fat cells.
These mechanisms are not just different — they're orthogonal. One targets the supply side (how much fat is stored and mobilized). The other targets the demand side (how much food is consumed). This orthogonality makes combination research conceptually rational: could targeting both simultaneously produce effects beyond either approach alone?
Comparison Table
| Attribute | AOD-9604 | GLP-1 Agonists (GLP-1(S), GLP-2(T)) |
|---|---|---|
| Mechanism | Direct lipolysis in adipose tissue | Appetite suppression + insulin signaling |
| Target | Beta-3 adrenergic receptors on adipocytes | GLP-1R (± GIP-R) in brain and pancreas |
| Appetite Effect | None | Strong appetite suppression |
| Insulin Effect | None | Enhanced glucose-dependent insulin secretion |
| IGF-1 Effect | None | None |
| Fat Targeting | Direct (breaks down stored fat) | Indirect (reduces caloric intake → fat loss) |
| Anti-Lipogenic | Yes (inhibits new fat synthesis) | Not primary mechanism |
| Clinical Evidence | Phase 2 (safety confirmed, efficacy mixed) | Phase 3 (extensive, strong efficacy) |
| Origin | GH fragment (amino acids 177-191) | Incretin hormone analogs |
The Evidence Gap
GLP-1 agonists have dramatically stronger clinical evidence. Phase 3 trials with thousands of participants show 15-24% body weight reduction. The evidence is robust, replicated, and FDA-approved.
AOD-9604's clinical evidence is weaker. The Phase 2 oral trial confirmed safety but didn't meet its primary weight loss endpoint. Whether this reflects the compound's biology or the trial design (oral delivery of a peptide, potentially suboptimal dosing) is debated.
In preclinical models (obese Zucker rats), AOD-9604 clearly reduces body fat. The preclinical-to-clinical translation gap remains the main question mark.
When to Use Which
GLP-1 agonists for protocols studying incretin signaling, appetite biology, glucose metabolism, or when the strongest available clinical evidence base is required.
AOD-9604 for protocols requiring direct adipose tissue intervention without appetite or insulin confounders, for studying GH-fragment biology specifically, or for fat metabolism research where central appetite signaling is not the variable of interest.
Both for combination protocols testing whether direct lipolysis + appetite suppression produces additive effects.
Explore the Related Compounds
Jump from the journal into the matching catalog pages to inspect specs, pricing, citations, and the batch-specific COA.
AOD-9604
AOD-9604 is a synthetic peptide fragment of human growth hormone (hGH), comprising amino acids 176–191. Designed to focus on fat metabolism without affecting IGF-1 or glucose levels, it is widely studied in metabolic and obesity-related research. AOD-9604 is intended exclusively for controlled laboratory use in scientific research.
GLP – 1 (S)
GLP – 1 (S) is a synthetic GLP-1 receptor agonist peptide developed for the investigation of glucose regulation, insulin signaling, and appetite pathways. It is structurally modified to resist enzymatic degradation and prolong half-life. GLP – 1 (S) is supplied for controlled laboratory research and is not intended for human or veterinary use.
GLP – 2 (T)
GLP – 2 (T) is a synthetic peptide designed as a dual agonist of GIP and GLP-1 receptors. It is studied for its effects on glycemic control, insulin signaling, and appetite regulation in metabolic research. GLP – 2 (T) is intended strictly for laboratory research use and is not approved for human or veterinary application.
Frequently Asked Questions
Questions About AOD-9604 vs GLP-1 Agonists
Scientifically rational — they target orthogonal mechanisms (direct lipolysis vs appetite signaling). No published combination data exists.
GLP-1 agonists, overwhelmingly. Phase 3 clinical data with large sample sizes. AOD-9604 has Phase 2 data with mixed results.
No. Zero appetite effect. This is both its limitation (doesn't address caloric intake) and its strength (clean fat-specific research tool).
They answer different research questions. GLP-1 agonists for appetite/incretin biology. AOD-9604 for direct adipose tissue metabolism.
Some researchers argue the oral delivery route was suboptimal for a peptide fragment and that parenteral dosing might have shown efficacy. This is speculative.
No. Confirmed in clinical trials — no effect on glucose, insulin, or IGF-1.
Keep Following the Research Trail
AOD-9604 — Isolating the Fat-Burning Fragment of Growth Hormone
AOD-9604 growth hormone fragment research overview. Lipolysis, anti-lipogenesis, cartilage research, metabolic safety. PubMed cited.
GLP-1 vs GLP-2 vs GLP-3 — The Incretin Agonist Progression
Complete comparison of single (semaglutide), dual (tirzepatide), and triple (retatrutide) incretin agonists. Receptors, data, research applications.
Metabolic Peptides — Incretin Agonism, Fat Metabolism, and Exercise Mimetics
Complete guide to metabolic research compounds. Incretin agonists, lipolysis, AMPK, exercise mimetics. Single/dual/triple agonism compared.